Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 925-933

  Shackleford, David M ^a   Faassen, W A ^b   Houwing, Natalie ^b   Lass, Holger ^c   Edwards, Glenn A ^b   Porter, Christopher J H ^a,d   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

^b NV Organon ^*

^c Organon Development GmbH   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDRIOL TESTOCAPS; TESTOSTERONE UNDECANOATE;

ANIMAL EXPERIMENT; ARTICLE; CANNULATION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG INACTIVATION; DRUG TRANSPORT; FIRST PASS EFFECT; HYDROLYSIS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; THORACIC DUCT;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CATHETERIZATION; DIHYDROTESTOSTERONE; DOGS; FEMALE; LYMPH; LYMPHATIC SYSTEM; MALE; TESTOSTERONE;

EID: 0041430944     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052522     Document Type: Article

References (29)

1. Baba S, Shinohara Y, and Kasuya Y (1979) Determination of plasma testosterone by mass fragmentography using testosterone-19-d3 as an internal standard. Comparison with radioimmunoassay. J Chromatogr A 162:529-537.
2. Baba S, Shinohara Y, and Kasuya Y (1980) Differentiation between endogenous and exogenous testosterone in human plasma and urine after oral administration of deuterium-labeled testosterone by mass fragmentography. J Clin Endocrinol Metab 50:889-894.
3. Bagchus WM, Hust R, Maris F, Schnabel PG and NSH (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319-325.
4. Carani C, Zini D, Baldini A, Della Casa L, Ghizzani A, and Marrama P (1990) Effects of androgen treatment in impotent men with normal and low levels of free testosterone. Arch Sex Behav 19:223-234.
5. Coert A, Geelen J, de Visser J, and van der Vies J (1975) The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol 79:789-800.
6. Daggett PR, Wheeler MJ, and Nabarro JD (1978) Oral testosterone, a reappraisal. Horm Res 9:121-129.
7. Edwards GA, Porter CJH, Caliph SM, Khoo SM, and Charman WN (2001) Animal models for the study of intestinal lymphatic drug transport [Review]. Adv Drug Deliv Rev 50:45-60.
8. Frey H, Aakvaag A, Saanum D, and Falch J (1979) Bioavailability of oral testosterone in males. Eur J Clin Pharmacol 16:345-349.
9. Fujioka M, Shinohara Y, Baba S, Irie M, and Inoue K (1986) Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 63:1361-1364.
10. Fujioka M, Shinohara Y, Baba S, Irie M, and Inoue K (1989) Endogenous and exogenous testosterone levels after administration of deuterium-labelled testosterone propionate in hypogonadotropic hypogonadism. Chem Pharm Bull 37: 3100-3101.
11. Geurts TBP and Coelingh Bennink HJT (2000) Testosterone replacement therapy-testosterone undecanoate (Andriol). J Urol Urogenakol Special Edition:24-35.
12. Gooren LJ (1994) A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 15:212-215.
13. Heck HdA, Buttrill SEJ, Flynn NW, Dyer RL, Anbar M, Cairns T, Dighe S, and Cabana BE (1979) Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests. J Pharmacokinet Biopharm 7:233-248.
14. Hirschhauser C, Hopkinson CR, Sturm G, and Coert A (1975) Testosterone undecanoate: a new orally active androgen. Acta Endocrinol 80:179-187.
15. Horst HJ, Holtje WJ, Dennis M, Coert A, Geelen J, and Voigt KD (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klinische Wochenschrift 54:875-879.
16. Humberstone AJ, Porter CJ, and Charman WN (1996) A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 85:525-529.
17. Khoo SM, Edwards GA, Porter CJH, and Charman WN (2001) A conscious dog model for assessing the absorption, enterocyte-based metabolism and intestinal lymphatic transport of halofantrine. J Pharm Sci 90:1599-1607.
18. Khoo SM, Prankerd RJ, Edwards GA, Porter CJH, and Charman WN (2002) A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. J Pharm Sci 91:647-659.
19. Luisi M and Franchi F (1980) Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Investig 3:305-308.
20. Maisey NM, Bingham J, Marks V, English J, and Chakraborty J (1981) Clinical efficacy of testosterone undecanoate in male hypogonadism. Clin Endocrinol 14: 625-629.
21. Mårin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, and Björntorp P (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity 16:991-997.
22. Morales A, Johnston B, Heaton JP, and Lundie M (1997) Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157:849-854.
23. Noguchi T, Charman WNA, and Stella VJ (1985) The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm 24:173-184.
24. O'Carroll R, Shapiro C, and Bancroft J (1985) Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol 23:527-538.
25. Shinohara Y and Baba S (1990) Stable isotope methodology in the pharmacokinetic studies of androgenic steroids in humans. Steroids 55:170-176.
26. Shinohara Y, Baba S, and Kasuya Y (1980) Absorption, metabolism and excretion of oral testosterone in humans by mass fragmentography. J Clin Endocrinol Metab 51:1459-1462.
27. Shinohara Y, Fujioka M, and Baba S (1988) Pharmacokinetic studies of testosterone propionate using gas chromatography/mass spectrometry/selected ion monitoring. Biomed Environ Mass Spectrom 16:241-244.
28. Skakkebaek NE, Bancroft J, Davidson DW, and Warner P (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol 14:49-61.
29. Tauber U, Schroder K, Dusterberg B, and Matthes H (1986) Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet 11:145-149.